PDF(Pubmed)
Abstract：
UNASSIGNED: Post-Transplant Diabetes Mellitus (PTDM) affects 20%-40% of lung transplant recipients within five years, impacting rejection, infection, cardiovascular events, and mortality. Continuous glucose monitoring (CGM) is used in diabetes but not well-studied in PTDM.
UNASSIGNED: This study assessed CGM performance in detecting hypoglycemia and hyperglycemia post-lung transplantation, compared to self-monitoring blood glucose.
UNASSIGNED: A prospective pilot study included 15 lung transplant patients (mean age 58.6 years; 53.3% men; 73.3% with pre-transplantation diabetes) managing hyperglycemia with insulin. Patients used a blinded CGM and self-monitored glucose for ten days. Data were categorized (% time in range, % high, % very high, % low, % very low) and compared using paired t-tests.
UNASSIGNED: CGM showed superior hyperglycemia detection. Mean differences for \"% very high\", \"% high\", and \"% high and % very high\" were 7.12 (95% CI, 1.8-12.4), 11.1 (95% CI, 3.5-18.8), and 18.3 (95% CI: 7.37-29.24), respectively. No significant difference was found for \"% low and % very low\". All patients reported a positive CGM experience.
UNASSIGNED: CGM use post-lung transplantation seems feasible and offers advantages in detecting hyperglycemia and in optimizing glucose management. Study limitations include a small sample size, requiring larger studies to assess glycemic control, hypoglycemia detection, and transplant outcomes.
UNASSIGNED: This study assessed CGM performance in detecting hypoglycemia and hyperglycemia post-lung transplantation, compared to self-monitoring blood glucose.
UNASSIGNED: A prospective pilot study included 15 lung transplant patients (mean age 58.6 years; 53.3% men; 73.3% with pre-transplantation diabetes) managing hyperglycemia with insulin. Patients used a blinded CGM and self-monitored glucose for ten days. Data were categorized (% time in range, % high, % very high, % low, % very low) and compared using paired t-tests.
UNASSIGNED: CGM showed superior hyperglycemia detection. Mean differences for \"% very high\", \"% high\", and \"% high and % very high\" were 7.12 (95% CI, 1.8-12.4), 11.1 (95% CI, 3.5-18.8), and 18.3 (95% CI: 7.37-29.24), respectively. No significant difference was found for \"% low and % very low\". All patients reported a positive CGM experience.
UNASSIGNED: CGM use post-lung transplantation seems feasible and offers advantages in detecting hyperglycemia and in optimizing glucose management. Study limitations include a small sample size, requiring larger studies to assess glycemic control, hypoglycemia detection, and transplant outcomes.
摘要：
■移植后糖尿病（PTDM）在五年内影响20％-40％的肺移植受者，影响拒绝，感染,心血管事件,和死亡率。连续血糖监测（CGM）用于糖尿病，但在PTDM中尚未得到充分研究。
■这项研究评估了CGM在检测肺移植后低血糖和高血糖方面的表现，与自我监测血糖相比。
■一项前瞻性试点研究包括15例肺移植患者（平均年龄58.6岁；53.3%男性；73.3%患有移植前糖尿病）使用胰岛素治疗高血糖症。患者使用盲化CGM并自我监测葡萄糖10天。数据已分类(%时间范围,%高,%非常高,%低,%非常低)，并使用配对t检验进行比较。
■CGM显示出优越的高血糖检测。“%非常高”的平均差异，\"%high\",“%高”和“%非常高”为7.12(95%CI，1.8-12.4)，11.1（95%CI，3.5-18.8），和18.3（95%CI：7.37-29.24），分别。“%低”和“%非常低”没有发现显著差异。所有患者都报告了积极的CGM经历。
■CGM使用肺移植后似乎是可行的，并且在检测高血糖和优化葡萄糖管理方面具有优势。研究限制包括样本量小，需要更大规模的研究来评估血糖控制，低血糖检测，和移植结果。
■这项研究评估了CGM在检测肺移植后低血糖和高血糖方面的表现，与自我监测血糖相比。
■一项前瞻性试点研究包括15例肺移植患者（平均年龄58.6岁；53.3%男性；73.3%患有移植前糖尿病）使用胰岛素治疗高血糖症。患者使用盲化CGM并自我监测葡萄糖10天。数据已分类(%时间范围,%高,%非常高,%低,%非常低)，并使用配对t检验进行比较。
■CGM显示出优越的高血糖检测。“%非常高”的平均差异，\"%high\",“%高”和“%非常高”为7.12(95%CI，1.8-12.4)，11.1（95%CI，3.5-18.8），和18.3（95%CI：7.37-29.24），分别。“%低”和“%非常低”没有发现显著差异。所有患者都报告了积极的CGM经历。
■CGM使用肺移植后似乎是可行的，并且在检测高血糖和优化葡萄糖管理方面具有优势。研究限制包括样本量小，需要更大规模的研究来评估血糖控制，低血糖检测，和移植结果。
